ArticleEvolutionary applications2012
Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms.
Article in Evolutionary applications, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 94 citations in OpenAlex.
- Antibiotic susceptibility of Staphylococcus aureus isolated from subclinical bovine mastitis cases and in vitro efficacy of bacteriophage.Veterinary research communications · 2018Trial
- Microbial interactions as key players shaping the emergence and spread ofMicrobiology (Reading, England) · 2026Review
- Phages tame plant pathogens.Nature microbiology · 2026Article
- Decoding phage communication: molecular networks, evolutionary dynamics, and therapeutic applications.NPJ biofilms and microbiomes · 2026Review
- Review
- Phage treatment of multidrug-resistant bacterial infections in humans, animals, and plants: The current status and future prospects.Infectious medicine · 2025Review
- The Potential of Bacteriophage-Antibiotic Combination Therapy in Treating Infections with Multidrug-Resistant Bacteria.Antibiotics (Basel, Switzerland) · 2023Review
- AIEgen-Based Nanomaterials for Bacterial Imaging and Antimicrobial Applications: Recent Advances and Perspectives.Molecules (Basel, Switzerland) · 2023Review
- Phages against killer superbugs: An enticing strategy against antibiotics-resistant pathogens.Frontiers in pharmacology · 2023Review
- Resistance-resistant antibacterial treatment strategies.Frontiers in antibiotics · 2023Article
- Shigella viruses Sf22 and KRT47 require outer membrane protein C for infection.Biochimica et biophysica acta. Biomembranes · 2022Article
- Nanoparticles Influence Lytic Phage T4-like Performance In Vitro.International journal of molecular sciences · 2022Article
- Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistantComputational and structural biotechnology journal · 2022Article
- Climatic Alterations Influence Bacterial Growth, Biofilm Production and Antimicrobial Resistance Profiles inAntibiotics (Basel, Switzerland) · 2021Article
- Bacteriophage Resistance Affects Flavobacterium columnare Virulence Partly via Mutations in Genes Related to Gliding Motility and the Type IX Secretion System.Applied and environmental microbiology · 2021Article
- Anthropogenic chemicals and their impacts on microbes living in buildings.Microbial biotechnology · 2021Article
- Phage Therapy in Veterinary Medicine.Antibiotics (Basel, Switzerland) · 2021Review
- Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis.International journal of molecular sciences · 2021Review
- Aztreonam Lysine Increases the Activity of Phages E79 and phiKZ againstMicroorganisms · 2021Article
- Bacteriophage Therapy as a Potential Management Option for Surgical Wound Infections.PHAGE (New Rochelle, N.Y.) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution of multi-antibiotic resistance in bacterial pathogens, often resulting from de novo mutations, is creating a public health crisis. Phages show promise for combating antibiotic-resistant bacteria, the efficacy of which, however, may also be limited by resistance evolution. Here, we suggest that phages may be used as supplements to antibiotics in treating initially sensitive bacteria to prevent resistance evolution, as phages are unaffected by most antibiotics and there should be little cross-resistance to antibiotics and phages. In vitro experiments using the bacterium Pseudomonas fluorescens, a lytic phage, and the antibiotic kanamycin supported this prediction: an antibiotic-phage combination dramatically decreased the chance of bacterial population survival that indicates resistance evolution, compared with antibiotic treatment alone, whereas the phage alone did not affect bacterial survival. This effect of the combined treatment in preventing resistance evolution was robust to immigration of bacteria from an untreated environment, but not to immigration from environment where the bacteria had coevolved with the phage. By contrast, an isogenic hypermutable strain constructed from the wild-type P. fluorescens evolved resistance to all treatments regardless of immigration, but typically suffered very large fitness costs. These results suggest that an antibiotic-phage combination may show promise as an antimicrobial strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.